Bullous Pemphigoid
Conditions
Brief summary
This study was designed to be a retrospective, multicentre, observational study to evaluate the efficacy and safety of dupilumab in the treatment of bullous pemphigoid and to find predictors of efficacy.
Interventions
DRUGDupilumab
Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.
Sponsors
Ruijin Hospital
Chinese Academy of Medical Sciences
West China Hospital
Second Xiangya Hospital of Central South University
Shandong Provincial Institute of Dermatology and Venereology
Peking University First Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult bullous pemphigoid patients treated with dupilumab between January 1, 2021, and July 31, 2022, at six leading dermatology departments in the Chinese Collaborative Network for Autoimmune Bullous Diseases. * The diagnosis of BP requires clinical manifestations and immunological or pathological evidences. * Dupilumab treatment should continue for at least 4 weeks and possibly longer.
Exclusion criteria
* Drug-induced BP, γ-1 pemphigoid * Patients with less than 4 weeks of follow-up * Patients were given any other biologicals within 6 months before the first dupilumab administration
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients reached disease control | within 4 weeks | Disease control was defined as the point at which new lesions or pruritic symptoms cease to form and existing lesions start to heal. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relapse rate | within 64 weeks | Relapse was defined as the appearance of three or more new lesions a month or at least one eczematous lesion with a diameter \>10cm or urticarial plaque that does not heal within one week, or the extension of established lesions or daily pruritus in a patient who has achieved disease control. |
| Adverse events | within 64 weeks | Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. |
| Changes in BPDAI scores | from 0 to 64 weeks | Disease severity was assessed using the bullous pemphigoid disease area index (BPDAI) score and was classified into mild (BPDAI≤19), moderate (20≤BPDAI≤56), and severe (BPDAI≥57). |
| Changes in itching NRS scores | from 0 to 64 weeks | Pruritus was evaluated via itching numeric rating scale (NRS), ranging from 0 (no itch) to 10 points (worst imaginable itch). |
| Complete remission rate | within 64 weeks | Complete remission is defined as the absence of new or established lesions or pruritus while the patient is receiving minimal therapy or off therapy for at least 2 months. |
| Changes in serum anti-BP230 antibodies | from 0 to 64 weeks | — |
| Changes in serum total IgE | from 0 to 64 weeks | — |
| Changes in peripheral blood eosinophil count | from 0 to 64 weeks | — |
| Changes in serum anti-BP180 antibodies | from 0 to 64 weeks | — |
Countries
China
Outcome results
None listed